Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants

Pediatric Infectious Disease Journal

Volumn 32, Issue 9, 2013, Pages 956-961

  Cohen Wolkowiez, Michael ^a   Sampson, Mario ^a   Bloom, Barry T ^b   Arrieta, Antonio ^c   Wynn, James L ^d   Martz, Karen ^e   Harper, Barrie ^a   Kearns, Gregory L ^f   Capparelli, Edmund V ^g   Siegel, David ^h   Benjamin Jr , Daniel K ^a   Smith, P Brian ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b Wichita Medical Research and Education Foundation   (United States)

^c CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e EMMES CORPORATION   (United States)

^f UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Dried blood spots; Drug; Metronidazole; Neonate; Pharmacokinetics

Indexed keywords

METRONIDAZOLE;

ACCURACY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRIED BLOOD SPOT TESTING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; MALE; MONTE CARLO METHOD; MULTICENTER STUDY; OPEN STUDY; PREMATURITY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ANTI-INFECTIVE AGENTS; BLOOD CHEMICAL ANALYSIS; DESICCATION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; MALE; METRONIDAZOLE; MODELS, THEORETICAL; PROSPECTIVE STUDIES; SPECIMEN HANDLING;

EID: 85047686952     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182947cf8     Document Type: Article

References (23)

1. Uhari M, Seppanen J, Heikkinen E. Imipenem-cilastatin vs. tobramycin and metronidazole for appendicitis-related infections. Pediatr Infect Dis J. 1992;11:445-450.
2. Brook I. Bacteremia due to anaerobic bacteria in newborns. J Perinatol. 1990;10:351-356.
3. Thompson AM, Bizzarro MX Necrotizing enterocolitis in newborns: pathogenesis, prevention and management. Drugs. 2008;68:1227-1238.
4. Vohr BR, Wright LL, Dusick AM, et al. Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993-1994. Pediatrics. 2000;105:1216-1226.
5. Yeh TC, Chang JH, Kao HA, et al. Necrotizing enterocolitis in infants: clinical outcome and influence on growth and neurodevelopment. J Formos Med Assoc. 2004;103:761-766.
6. Neofax 2011. 24th ed. Montvale, NJ: Thomson Reuters; 2011.
7. Tschudy M, Arcara K. The Harriet Lane Handbook: A Manual for Pediatric House Officers. 19th ed. Philadelphia, PA: Mosby; 2011.
8. Houghton GW, Smith J, Thorne PS, et al. The pharmacokinetics of oral and intravenous metronidazole in man. J Antimicrob Chemother. 1979;5:621-623.
9. Upadhyaya P, Bhatnagar V, Basu N. Pharmacokinetics of intravenous metronidazole in neonates. J Pediatr Surg. 1988;23:263-265.
10. Cohen-Wolkowiez M, Ouellet D, Smith PB, et al. Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants. Antimicrob Agents Chemother. 2012;56:1828-1837.
11. Suyagh M, Collier PS, Millership JS, et al. Metronidazole population pharmacokinetics in preterm neonates using dried blood-spot sampling. Pediatrics. 2011;127:e367-e374.
12. Smith PB, Cohen-Wolkowiez M, Castro LM, et al.; Meropenem Study Team. Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections. Pediatr Infect Dis J. 2011;30:844-849.
13. Ette EI, Williams PJ, Kim YH, et al. Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol. 2003;43:610-623.
14. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard. 7th ed. CLSI document M11-A7. Wayne, PA: Clinical and Laboratory Standards Institute; 2007.
15. Lamp KC, Freeman CD, Klutman NE, et al. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet. 1999;36:353-373.
16. Koeth LM, Good CE, Appelbaum PC, et al. Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents. J Antimicrob Chemother. 2004;53:1039-1044.
17. Nagy E, Urban E, Nord CE; ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience. Clin Microbiol Infect. 2011;17:371-379.
18. Metronidazole drug label. Available at: http://www.accessdata.fda.gov/ scripts/cder/drugsatfda/index.cfm?fuseaction=Search. SearchAction&Searc hType=BasicSearch&searchTerm=metronidazole&Search-Button=Submit. Accessed November 20, 2012.
19. Ludwig E, Csiba A, Magyar T, et al. Uptake of metronidazole by human erythrocytes. Acta Med Acad Sci Hung. 1981;38:163-170.
20. Jensen JC, Gugler R. Single- and multiple-dose metronidazole kinetics. Clin Pharmacol Ther. 1983;34:481-487.
21. Sherwin CM, Svahn S, Van Der Linden A, et al. Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. Eur J Clin Pharmacol. 2009;65:705-713.
22. Marques-Minana MR, Saadeddin A, Peris JE. Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline. Br J Clin Pharmacol. 2010;70:713-720.
23. Palmer GM, Atkins M, Anderson BJ, et al. I. V acetaminophen pharmacokinetics in neonates after multiple doses. Br J Anaesth. 2008;101:523-530.